Articles On Immutep (ASX:IMM)
Title | Source | Codes | Date |
---|---|---|---|
ASX Today: Stocks to watch on Monday
The ASX is expected to rise on a fresh week, with eyes on US earnings as companies prepare to report this week. Ahead of a new week and market opening in Australia, here are some ASX-listed companies to look out for during Monday’s trade... |
themarketherald.com.au | IMM | 1 year ago |
Dr Boreham’s Crucible: Radiopharm Theronostics
Dr Boreham’s Crucible: Radiopharm Theronostics By Tim Boreham ASX code: ((RAD)); NASDAQ code (proposed): RADX Share price: 14.5 cents Market cap: $49.15 million Shares on issue: 238,947,639 (100,000,000 more in ASX escrow) Chief executive o... |
FNArena | IMM | 1 year ago |
Immutep announces changes to its board of directors
Immutep (ASX:IMM), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune diseases, has announced that Lis Boyce has been appointed as a non-executive director. |
BiotechDispatch | IMM | 1 year ago |
Gains from materials and healthcare boost ASX 0.71% at noon
ShareCafeGains from materials and healthcare boost ASX 0.71% at noon by Peter Milios At noon, the S&P/ASX 200 is 0.71 per cent higher at 7,172.90, with materials and healthcare sectors leading the gains. Syrah Resources (ASX:SYR), Blo... |
ShareCafe | IMM | 1 year ago |
Stocks of the Hour: NOVONIX, Immutep, Sayona Mining
31 Mar 2023 - A snapshot of the stocks on the move featuring NOVONIX (ASX:NVX), Immutep Limited (ASX: IMM; NASDAQ:IMMP) and Sayona Mining (ASX:SYA). |
FNN | IMM | 1 year ago |
Stocks of the Hour: NVX, IMM, SYA
ShareCafeStocks of the Hour: NVX, IMM, SYA NOVONIX (NASDAQ:NVX, ASX:NVX) announced that it has agreed to establish a joint venture with TAQAT to develop and produce anode materials for electric vehicle and energy st... |
ShareCafe | IMM | 1 year ago |
ASX falls 1.4% to three-month low
ShareCafeASX falls 1.4% to three-month low by Peter Milios At the closing bell, the S&P/ASX 200 was 1.4 per cent lower at 7,008.9, a three-month low. The fall was mainly due to concerns about a financial crisis after the collapse of U... |
ShareCafe | IMM | 1 year ago |
ASX down 1.91% at noon to lowest point since Jan
ShareCafeASX down 1.91% at noon to lowest point since Jan by Peter Milios Earlier today, the S&P/ASX 200 stock index of Australia experienced a decline of 2.1 per cent and hit a new low of 6956.7, which is close to its lowest point of... |
ShareCafe | IMM | 1 year ago |
Stocks of the Hour: Patrys, Mt Monger Resources, Immutep
14 Mar 2023 - A snapshot of the stocks on the move featuring Patrys (ASX:PAB), Mt Monger Resources (ASX:MTM) and Immutep (ASX:IMM). |
FNN | IMM | 1 year ago |
Stocks of the Hour: PAB, MTM, IMM
ShareCafeStocks of the Hour: PAB, MTM, IMM Patrys (ASX:PAB) has announced that their preclinical data supports synthetic lethality mechanisms to treat relevant cancers. Patrys Chief Executive Officer and Managing Di... |
ShareCafe | IMM | 1 year ago |
Immutep announces the initiation of a new breast cancer trial
Immutep (ASX:IMM) has announced the initiation of the AIPAC-003 clinical trial evaluating its eftilagimod alpha in combination with paclitaxel for the treatment of metastatic HER2-neg/low breast cancer. |
BiotechDispatch | IMM | 1 year ago |
The Week that Was: February 27-March 3, 2023
ShareCafeThe Week that Was: February 27-March 3, 2023 We at ShareCafe understand you are busy and may not have been left with enough time to keep up with the quality content we’ve been bringing you throughout the week. To make it easier to... |
ShareCafe | IMM | 1 year ago |
Immutep (ASX: IMM) Delivering Strong Lung Cancer Data
ShareCafeImmutep (ASX: IMM) Delivering Strong Lung Cancer Data Immutep Limited (ASX:IMM) Executive Director and CEO Marc Voigt discusses data from SITC, the strategy to take Efti to market and milestones for 2023. Tim McGowen: We’re talk... |
ShareCafe | IMM | 1 year ago |
Immutep (ASX: IMM) – Webinar Presentation
ShareCafeImmutep (ASX: IMM) – Webinar Presentation Marc Voigt – Executive Director & CEO – Immutep is a leading biotechnology company focused on developing effective autoimmune and cancer immunotherapy treatments such as Lag-3. Immutep... |
ShareCafe | IMM | 1 year ago |
Webinar Recap – Shaw and Partners, IMM, RAD, PET & IMD
ShareCafeWebinar Recap – Shaw and Partners, IMM, RAD, PET & IMD Catch up on the full webinar Shaw and Partners, Immutep (ASX: IMM), Radiopharm Theranostics (ASX: RAD), Phoslock Environmental Technologies (ASX: PET) & Imdex (ASX: IM... |
ShareCafe | IMM | 1 year ago |
Immutep reaches enrolment target for INSIGHT-003 trial in first line NSCLC
Australian clinical-stage biotechnology company Immutep (ASX:IMM) has announced that the investigator-initiated INSIGHT-003 trial has reached its enrolment target of 20 patients with first-line Non-small cell lung cancer. |
BiotechDispatch | IMM | 1 year ago |
Property sector leads ASX 0.3% lower
ShareCafeProperty sector leads ASX 0.3% lower by Peter Milios Large property players Goodman Group (ASX:GMG), Dexus (ASX:DXS), Mirvac Group (ASX:MGR) and Charter Hall (ASX:CHC) have all suffered losses in today’s session. The index has re... |
ShareCafe | IMM | 1 year ago |
ASX 0.1% lower at noon after all US indices fell over the weekend
ShareCafeASX 0.1% lower at noon after all US indices fell over the weekend by Peter Milios At noon, the S&P/ASX 200 is 0.1 per cent lower at 7,549.20. All sectors besides Energy and Materials are trading lower today, after the US sect... |
ShareCafe | IMM | 1 year ago |
Check Up: The FDA refuses to give CBD a green light, but market doesn’t seem to care
The FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have grown exponentially in the marketplace We take a look at what it all means for the cannabis industry The US FDA announced last week that:... |
Stockhead | IMM | 1 year ago |
Iron ore surge not enough to lift the ASX: Aus shares close 0.16% lower
ShareCafeIron ore surge not enough to lift the ASX: Aus shares close 0.16% lower by Peter Milios Iron ore prices have reached a seven-month high due to increased demand expectations from China after its reopening following a Covid-19 surg... |
ShareCafe | IMM | 1 year ago |
ASX down 0.15% at noon despite spike in US markets
ShareCafeASX down 0.15% at noon despite spike in US markets by Peter Milios The global race for lithium, a commodity crucial for the electric vehicle (EV) industry, has intensified as German Chancellor Olaf Scholz signed an agreement with... |
ShareCafe | IMM | 1 year ago |
Check Up: Japan’s startup OUI wants to halve the world’s blindness with its smartphone device
Japanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based device Which ASX healthcare companies also have smartphone-based products? A quick look at the best and worst ASX healthcare stocks over the past... |
Stockhead | IMM | 1 year ago |
Market Highlights: Tesla, oil prices slump, and 5 ASX small caps to watch on Wednesday
The ASX will open higher this morning, defying a slump in New York Tesla shares plunged 12% Oil prices tumbled on recession fears Aussie shares are set to open higher this morning despite a fall in New York. At 8am AEDT, the ASX 200 Jan... |
Stockhead | IMM | 1 year ago |
Immutep (ASX:IMM) enrols 50pc of patients for TACTI-003 trial
Immutep (IMM) completes 50 per cent of patient enrolment for its TACTI-003 phase IIb trial The trial is designed to evaluate Immutep’s first-in-class soluble LAG-3 protein, efti, in combination with KEYTRUDA as first line treatment of re... |
themarketherald.com.au | IMM | 1 year ago |
ASX December Winners: Who’s led the way for small caps in tough month for global markets?
Little joy for investors in December with traditional Christmas rally not eventuating in 2022 Meteoric Resources leads December winners after positive metallurgical results at its new Caldeira project. Symbio Holdings saw its share price p... |
Stockhead | IMM | 1 year ago |
The A to Z of Dr Boreham’s Crucible in 2022
The long and short of 2022 is that it was a frustrating period for the Australian biotech sector but one with its fair share of rewards as the sector’s exponents furthered worthy drugs, diagnostics, devices and doodahs. For the sixth year,... |
Stockhead | IMM | 1 year ago |
In Brief: Insurers, Healthcare, Contractors, Classifieds, Retail
Weekly broker wrap: insurers more resilient, healthcare picks, contractors remain labour-reliant, classifieds look resilient, retail braces for decline. -Climate resilience supports domestic insurance outlook-Wilsons lists healthcare sector... |
FNArena | IMM | 1 year ago |
Lithium slammed by GS, NSW close to energy deal with Federal Government: ASX closes 0.6% lower
ShareCafeLithium slammed by GS, NSW close to energy deal with Federal Government: ASX closes 0.6% lower by Peter Milios Goldman Sachs have extended their bearish views on lithium, believing that the prices are expected to decline from the... |
ShareCafe | IMM | 1 year ago |
Lithium stocks under pressure following Goldman’s comments: ASX down 0.47% at noon
ShareCafeLithium stocks under pressure following Goldman’s comments: ASX down 0.47% at noon by Lauren Hayes The Australian market is still unnerved over concerns about a possible US recession. Energy is weighing down the benchmark over fe... |
ShareCafe | IMM | 1 year ago |
Immutep (ASX:IMM) achieves commercial scale manufacturing of efti
Immutep (IMM) achieves commercial scale manufacturing of its lead product candidate, eftilagimod alpha (efti)The company completed its first 2000-litre manufacturing run of efti, a first-in-class soluble LAG-3 proteinImmutep has been workin... |
themarketherald.com.au | IMM | 1 year ago |
ASX Health Stocks: Imagion jumps 20pc after delivering positive Phase 1 results
Imagion presents positive data at world leading symposium Osteopore expands in Southeast Asia Microba expands into Italy and Portugal Imagion speaks at world-leading breast cancer symposium Imagion Biosystems (ASX:IBX) is set to rise ov... |
Stockhead | IMM | 1 year ago |
Shares dip following rate hike: ASX closes 0.5% lower
ShareCafeShares dip following rate hike: ASX closes 0.5% lower by Peter Milios The ASX has closed 0.47 per cent lower after the Reserve Bank of Australia delivered its eighth interest rate hike in a row, lifting the cash rate 25 basis hig... |
ShareCafe | IMM | 1 year ago |
Local market awaits RBA rate decision: ASX falls 0.17% at noon
ShareCafeLocal market awaits RBA rate decision: ASX falls 0.17% at noon by Lauren Hayes The Australian market has followed Wall Street’s negative lead overnight after US markets sold off on fears that the Fed will keep increasing interest... |
ShareCafe | IMM | 1 year ago |
Market Highlights: Rates day! And almost every US stock loses overnight as US economy picks up
Well, it’s rates day here in Oz, and property owners are donning their brownest pants for a likely rise. Some say 50bps is sensible. In the US, the Fed got a case to keep rising rates despite the inflationary slowdown. Stronger than expecte... |
Stockhead | IMM | 1 year ago |
The Week that Was: November 28-December 2, 2022
ShareCafeThe Week that Was: November 28-December 2, 2022 We at ShareCafe understand you are busy and may not have been left with enough time to keep up with the quality content we’ve been bringing you throughout the week. To make it easier... |
ShareCafe | IMM | 1 year ago |
ScoPo’s Powerplays: ASX health stocks dancing to a positive tune
ASX Health sector is continuing its upward trend, marginally up this week 0.87% Sonic Healthcare announces a plan to acquire ~20% holding of Microba Life Sciences Mayne Pharma shares takes a hit after company warns it won’t hit positive e... |
Stockhead | IMM | 1 year ago |
Iron ore climbs to highest price since September: ASX closes 0.3% higher
ShareCafeIron ore climbs to highest price since September: ASX closes 0.3% higher by Peter Milios Singaporean iron ore futures have soared above the US$100 per tonne for the first time since September, resulting in gains for ASX-listed ir... |
ShareCafe | IMM | 1 year ago |
Immutep (ASX:IMM) enters second collaboration with Pfizer and Merck KGaA for INSIGHT study
Immutep (IMM) signs another collaboration agreement with Merck KGaA, Darmstadt, Germany and Pfizer for a phase one clinical studyThe companies will conduct and jointly fund the INSIGHT-005 trial in Germany to evaluate Immutep’s efti product... |
themarketherald.com.au | IMM | 1 year ago |
Chinese protests over lockdowns continue: Aus shares 0.07% lower at noon
ShareCafeChinese protests over lockdowns continue: Aus shares 0.07% lower at noon by Peter Milios The global economic outlook is shaky, as growing protests in the world’s largest manufacturing nation are creating a new level of uncertaint... |
ShareCafe | IMM | 1 year ago |
ASX Health Stocks: Sonic snaps up stake in Microba, sending MAP share price 60pc higher
Sonic has taken a stake in Microba Immutep enters into second deal with Merck (Germany) and Pfizer ImpediMed has a new CEO Sonic takes strategic stake in Microba Giant healthcare stock Sonic Healthcare (ASX:SHL) has bought a stake in s... |
Stockhead | IMM | 1 year ago |
Immutep announces new collaboration for cancer treatment combination
Immutep (ASX:IMM) has announced a new clinical trial collaboration under which the Australian company's investigative LAG-3 immunotherapy, efti, will be studied with Merck and Pfizer's PBS-listed BAVENCIO (avelumab). |
BiotechDispatch | IMM | 1 year ago |
Market Highlights: China protests dampen investor mood, and 5 ASX small caps to watch on Tuesday
The ASX is set to open slightly higher on Tuesday Wall Street fell almost 2% overnight as protests in China spread Crypto lender BlockFi has filed for bankruptcy The ASX is poised to edge slightly higher on Tuesday despite a 1.5% – 1.75%... |
Stockhead | IMM | 1 year ago |
Immutep (ASX: IMM) – A Transformative Year for LAG-3 Therapies
ShareCafeImmutep (ASX: IMM) – A Transformative Year for LAG-3 Therapies Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt discusses the LAG-3 landscape, the company’s portfolio of therapies, encouraging data from the 2022 SIT... |
ShareCafe | IMM | 1 year ago |
How out of favour Biotech has a PR problem and could learn from Dr Karl
ASX health stocks have been out of favour this year with rotation away from growth to value sector Morgan’s Scott Power said a lot of biotechs aren’t able to convert their complex science into layman’s terms Hot money going to lithium and... |
Stockhead | IMM | 1 year ago |
Early gains quickly wiped off: ASX closes the day 0.16% lower
ShareCafeEarly gains quickly wiped off: ASX closes the day 0.16% lower by Peter Milios All sectors except Materials and Energy are lower in today’s day of trading, as the ASX finishes 0.16 per cent or 11.70 points lower at 7146.30. Materi... |
ShareCafe | IMM | 1 year ago |
ASX Close: Shares fade as global rally falters
The ASX gave up early gains as last week’s fierce global share rally showed signs of losing momentum. The S&P/ASX 200 touched a five-month high before fading to a loss of 12 points or 0.16 per cent. The decline came as Asian mar... |
themarketherald.com.au | IMM | 1 year ago |
Market losing momentum, materials the saviour: ASX flat at noon
ShareCafeMarket losing momentum, materials the saviour: ASX flat at noon by Lauren Hayes Last week’s gains have not continued with the same momentum this morning. Materials, up 3.4 per cent, is bolstering the local market following a rise... |
ShareCafe | IMM | 1 year ago |
ASX Update: Early gains evaporate as Fed talks down outlook
The share market touched a five-month high before shedding its gains as a decline in US futures undermined a China-fuelled rally in resource stocks. The S&P/ASX 200 rallied to within four points of 7200 for the first time since June.... |
themarketherald.com.au | IMM | 1 year ago |
Immutep (ASX:IMM) receives $986k R&D tax rebate
Immutep (IMM) receives a $986,000 tax refund from the Australian government’s research and development (R&D) tax incentive programThe cash rebate is mostly for money Immutep spent on its clinical study work during its 2021 financial yea... |
themarketherald.com.au | IMM | 1 year ago |
ASX 200 rises at open; Fortescue, Champion Iron up over 8%
Highlights Australian shares opened higher on Monday. The ASX 200 gained in the opening trade, rising 25.20 points, or 0.35%, to 7,183.20. On Friday, the benchmark index closed 2.8% higher at 7,158 points. Australian s... |
Kalkine Media | IMM | 1 year ago |